
April 24 (Reuters) - Caribou Biosciences Inc CRBU.O:
CARIBOU BIOSCIENCES ANNOUNCES STRATEGIC PIPELINE PRIORITIZATION WITH FOCUS ON CB-010 AND CB-011 ONCOLOGY PROGRAMS
CARIBOU BIOSCIENCES INC - TO REDUCE WORKFORCE BY 32%
CARIBOU BIOSCIENCES INC - DISCONTINUES GALLOP PHASE 1 TRIAL OF CB-010 FOR LUPUS
CARIBOU BIOSCIENCES INC - DISCONTINUES AMPLIFY PHASE 1 TRIAL OF CB-012 FOR AML
CARIBOU BIOSCIENCES INC - CHANGES EXPECTED TO EXTEND CASH RUNWAY INTO H2 2027
CARIBOU BIOSCIENCES INC - TO PRESENT DATA FROM CB-010 AND CB-011 IN H2 2025